Developing INSL5 analogs as colon motility regulator
More than 16% of the general population, and 32.5% of people aged 60-110, are affected by chronic colon motility disorders due to decreased constipation or increased diarrhoea. It’s expected that the prevalence of chronic colon motility disorders will continue to rise as the population ages.
Current therapies to treat constipation and diarrhoea are inefficient and/or have adverse side effects. It’s clear that new approaches and targets are required to advance gastrointestinal motility pharmacotherapy.
Further, the lead agonists and antagonists from pharmacological studies will be forwarded to the in vivo testing. The lead antagonists will be tested in animal models of diarrhoea, and agonists will be tested in animal models of constipation.
Aim
- Design and develop novel analogues of INSL5 as potential drug leads for chronic colon motility disorders.
In this project we’ll design and develop novel analogues of INSL5 as potential drug leads using modern solid phase peptide synthesis (SPPS). All analogues will be analysed, purified and characterised by a wide range of scientific techniques such as RP-HPLC, MALDI-TOF mass spectrometry, circular dichroism spectroscopy and nuclear magnetic resonance studies. All these analogues developed by various cutting-edge chemical approaches will also be screened using cell based (RXFP4) assays to test their binding and activity (e.g. competition binding assays and cAMP assays).
Research team
Take part in this project
Student applications
Students who are applying to study at The Florey can register their interest in this project. Refer to our step-by-step guide to help you with your application.
Contact us
If you’re interested in learning more about this project please contact our team.